The staging model in schizophrenia, and its clinical implications

Area of Science:

• Neuroscience
• Psychiatry

Background:

• Complex illnesses like schizophrenia benefit from a staged approach to treatment planning.
• This model, successful in cancer treatment, can be applied to schizophrenia.
• Understanding disease progression is crucial for effective therapeutic strategies.

Purpose of the Study:

• To describe a staging model for schizophrenia development.
• To present neuroimaging and clinical evidence supporting this model.
• To discuss the implications of schizophrenia staging for treatment.

Main Methods:

• Proposing a three-stage model: prodrome, first episode, and chronic phase.
• Utilizing European and global literature, including Australia, for data.
• Examining published literature against proposed staging criteria.

Main Results:

• Clinical data supports a three-stage progression: prodrome, first episode, chronic phase.
• A pre-morbid phase with neurodevelopmental delays may indicate future schizophrenia risk.
• Neuroimaging shows gray matter loss starting in the prodrome, paralleling cognitive changes.

Conclusions:

• Treatment strategies and expected outcomes differ across schizophrenia stages.
• Optimizing schizophrenia treatment requires stage-specific pharmacological and psychological interventions.
• Inappropriate treatment protocols can lead to suboptimal outcomes and iatrogenic harm.